|
16.10.2024 16:32:49
|
Upgrade of revenue and operating profit guidance
ANNOUNCEMENT NO. 279
16 October 2024
Upgrade of revenue and operating profit guidance
ChemoMetec sustained its positive performance in the first quarter of 2024/25 with better-than-expected sales and order intake.
Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 445-460 million range, up from DKK 435-450 million in the most recent guidance, and EBITDA in the DKK 222-230 million range, up from DKK 216-223 million previously.
ChemoMetec’s interim report for Q1 2024/25 is scheduled to be released on Thursday, 7 November 2024.
Additional information
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.
ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to www.chemometec.com.
Nachrichten zu ChemoMetec A-S
|
03.12.24 |
Upgrade of revenue and operating profit guidance (GlobeNewswire) | |
|
22.10.24 |
Closing of acquisition of Ovizio Imaging Systems SA (GlobeNewswire) | |
|
16.10.24 |
Acquisition of Ovizio Imaging Systems SA (GlobeNewswire) | |
|
16.10.24 |
Upgrade of revenue and operating profit guidance (GlobeNewswire) | |
|
11.10.24 |
ChemoMetec’s potential acquisition of Ovizio Imaging Systems SA (GlobeNewswire) |
3 neue Aktien 📈 im BX Musterportfolio: Trane Techn., Nasdaq Inc & Manhattan Ass. mit François Bloch
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
NEU✅ Trane Technologies
NEU✅ Nasdaq Inc
NEU✅ Manhattan Associates Inc
inklusive Rebalancing:
❌ Eli Lilly and Company
❌ Intesa Sanpaolo
❌ Unicredit
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| ChemoMetec A-S | 485.00 | 1.42% |
|
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Vor US-Arbeitsmarktdaten: SMI mit schwächerem Start erwartet -- DAX dürfte Rekord-Run unterbrechen -- Asiens Börsen uneinheitlich - Gewinne in ChinaDer heimische Aktienmarkt wird voraussichtlich mit Verlusten in den Handel einsteigen. Auch in Deutschland dürfte der Handel etwas schwächer starten. An den Börsen in Asien geht es am Freitag uneinheitlich zu.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |